nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2B—hematologic cancer	0.367	0.836	CbGaD
Dexrazoxane—TOP2B—Daunorubicin—hematologic cancer	0.172	0.416	CbGbCtD
Dexrazoxane—TOP2A—hematologic cancer	0.0719	0.164	CbGaD
Dexrazoxane—TOP2B—Etoposide—hematologic cancer	0.0661	0.159	CbGbCtD
Dexrazoxane—TOP2A—Idarubicin—hematologic cancer	0.0495	0.119	CbGbCtD
Dexrazoxane—TOP2A—Daunorubicin—hematologic cancer	0.035	0.0845	CbGbCtD
Dexrazoxane—TOP2A—Teniposide—hematologic cancer	0.0304	0.0734	CbGbCtD
Dexrazoxane—TOP2A—Mitoxantrone—hematologic cancer	0.0213	0.0513	CbGbCtD
Dexrazoxane—TOP2A—Epirubicin—hematologic cancer	0.0172	0.0416	CbGbCtD
Dexrazoxane—TOP2A—Etoposide—hematologic cancer	0.0134	0.0324	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—hematologic cancer	0.00915	0.0221	CbGbCtD
Dexrazoxane—TOP2B—hematopoietic system—hematologic cancer	0.00205	0.15	CbGeAlD
Dexrazoxane—TOP2B—gonad—hematologic cancer	0.00156	0.114	CbGeAlD
Dexrazoxane—TOP2B—blood—hematologic cancer	0.00136	0.0993	CbGeAlD
Dexrazoxane—TOP2B—bone marrow—hematologic cancer	0.00132	0.0961	CbGeAlD
Dexrazoxane—TOP2B—lung—hematologic cancer	0.00119	0.0871	CbGeAlD
Dexrazoxane—TOP2B—testis—hematologic cancer	0.00113	0.0821	CbGeAlD
Dexrazoxane—TOP2A—blood—hematologic cancer	0.001	0.073	CbGeAlD
Dexrazoxane—TOP2A—bone marrow—hematologic cancer	0.000968	0.0707	CbGeAlD
Dexrazoxane—TOP2A—lung—hematologic cancer	0.000877	0.064	CbGeAlD
Dexrazoxane—TOP2A—testis—hematologic cancer	0.000828	0.0604	CbGeAlD
Dexrazoxane—TOP2B—lymph node—hematologic cancer	0.000816	0.0595	CbGeAlD
Dexrazoxane—TOP2A—lymph node—hematologic cancer	0.0006	0.0438	CbGeAlD
Dexrazoxane—TOP2B—Topotecan—Irinotecan—hematologic cancer	0.000455	0.173	CbGdCrCtD
Dexrazoxane—TOP2A—G0 and Early G1—MYBL2—hematologic cancer	0.000398	0.049	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—MYBL2—hematologic cancer	0.000354	0.0435	CbGpPWpGaD
Dexrazoxane—TOP2B—Menadione—Thalidomide—hematologic cancer	0.000261	0.0996	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—hematologic cancer	0.00024	0.0296	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—DCK—hematologic cancer	0.000223	0.0275	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CEBPD—hematologic cancer	0.000223	0.0275	CbGpPWpGaD
Dexrazoxane—TOP2B—Teniposide—Etoposide—hematologic cancer	0.000205	0.0781	CbGdCrCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—H3F3A—hematologic cancer	0.000201	0.0248	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PPP1R13L—hematologic cancer	0.000197	0.0242	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—SMC3—hematologic cancer	0.000153	0.0189	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PER3—hematologic cancer	0.000143	0.0176	CbGpPWpGaD
Dexrazoxane—TOP2A—Nilotinib—Imatinib—hematologic cancer	0.000132	0.0505	CbGdCrCtD
Dexrazoxane—TOP2A—G0 and Early G1—CDK2—hematologic cancer	0.00013	0.016	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—hematologic cancer	0.000126	0.0155	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CRY1—hematologic cancer	0.000122	0.015	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CRY2—hematologic cancer	0.000122	0.015	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PER2—hematologic cancer	0.000122	0.015	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND3—hematologic cancer	0.000105	0.013	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—NOTCH1—hematologic cancer	0.000105	0.0129	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ID3—hematologic cancer	0.000103	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYBL2—hematologic cancer	0.000103	0.0127	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—HES1—hematologic cancer	9.44e-05	0.0116	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PER1—hematologic cancer	9.22e-05	0.0113	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—KMT2A—hematologic cancer	9.22e-05	0.0113	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—hematologic cancer	8.78e-05	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—hematologic cancer	8.52e-05	0.0105	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TOP1—hematologic cancer	8.43e-05	0.0104	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ID2—hematologic cancer	8.22e-05	0.0101	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK6—hematologic cancer	7.84e-05	0.00965	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RARA—hematologic cancer	7.83e-05	0.00964	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—hematologic cancer	7.43e-05	0.00915	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND3—hematologic cancer	7.41e-05	0.00912	CbGpPWpGaD
Dexrazoxane—TOP2A—Topotecan—Irinotecan—hematologic cancer	7.35e-05	0.028	CbGdCrCtD
Dexrazoxane—TOP2A—Etoposide—Teniposide—hematologic cancer	7.3e-05	0.0278	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—hematologic cancer	7.12e-05	0.00877	CbGpPWpGaD
Dexrazoxane—TOP2A—Vindesine—Vinorelbine—hematologic cancer	6.57e-05	0.025	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—ARNTL—hematologic cancer	6.57e-05	0.00809	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BBC3—hematologic cancer	6.49e-05	0.00798	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—ABL1—hematologic cancer	6.1e-05	0.00751	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUND—hematologic cancer	5.82e-05	0.00716	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—hematologic cancer	5.66e-05	0.00696	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—JUND—hematologic cancer	5.59e-05	0.00688	CbGpPWpGaD
Dexrazoxane—TOP2A—Podofilox—Teniposide—hematologic cancer	5.57e-05	0.0212	CbGdCrCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK6—hematologic cancer	5.52e-05	0.00679	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—hematologic cancer	5.52e-05	0.00679	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—hematologic cancer	5.49e-05	0.00675	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—hematologic cancer	5.35e-05	0.00658	CbGpPWpGaD
Dexrazoxane—TOP2A—Vindesine—Vinblastine—hematologic cancer	5.25e-05	0.02	CbGdCrCtD
Dexrazoxane—TOP2A—Vindesine—Vincristine—hematologic cancer	5.25e-05	0.02	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CST3—hematologic cancer	5.22e-05	0.00643	CbGpPWpGaD
Dexrazoxane—TOP2A—Floxuridine—Pentostatin—hematologic cancer	5.06e-05	0.0193	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—CST3—hematologic cancer	5.01e-05	0.00617	CbGpPWpGaD
Dexrazoxane—TOP2A—Idarubicin—Daunorubicin—hematologic cancer	4.96e-05	0.0189	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Daunorubicin—hematologic cancer	4.96e-05	0.0189	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Daunorubicin—hematologic cancer	4.96e-05	0.0189	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PML—hematologic cancer	4.92e-05	0.00605	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—hematologic cancer	4.79e-05	0.00589	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND2—hematologic cancer	4.74e-05	0.00584	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PML—hematologic cancer	4.72e-05	0.00581	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RAD1—hematologic cancer	4.66e-05	0.00574	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—hematologic cancer	4.52e-05	0.00557	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP7—hematologic cancer	4.47e-05	0.00551	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—hematologic cancer	4.39e-05	0.00541	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERF2—hematologic cancer	4.3e-05	0.0053	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—hematologic cancer	4.27e-05	0.00526	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2B—hematologic cancer	4.25e-05	0.00524	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RAD21—hematologic cancer	4.25e-05	0.00523	CbGpPWpGaD
Dexrazoxane—TOP2A—Menadione—Thalidomide—hematologic cancer	4.22e-05	0.0161	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—EZH2—hematologic cancer	4.1e-05	0.00505	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—SMC3—hematologic cancer	3.95e-05	0.00487	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—hematologic cancer	3.93e-05	0.00484	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—hematologic cancer	3.89e-05	0.00479	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—HDAC2—hematologic cancer	3.87e-05	0.00477	CbGpPWpGaD
Dexrazoxane—TOP2A—Cladribine—Pentostatin—hematologic cancer	3.83e-05	0.0146	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—RAD21—hematologic cancer	3.8e-05	0.00468	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYBL2—hematologic cancer	3.79e-05	0.00466	CbGpPWpGaD
Dexrazoxane—TOP2A—Doxorubicin—Idarubicin—hematologic cancer	3.76e-05	0.0143	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Idarubicin—hematologic cancer	3.76e-05	0.0143	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Idarubicin—hematologic cancer	3.76e-05	0.0143	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STAT1—hematologic cancer	3.62e-05	0.00445	CbGpPWpGaD
Dexrazoxane—TOP2A—Vincristine—Vinorelbine—hematologic cancer	3.55e-05	0.0135	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—SMC3—hematologic cancer	3.53e-05	0.00435	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AR—hematologic cancer	3.5e-05	0.0043	CbGpPWpGaD
Dexrazoxane—TOP2A—Cladribine—Clofarabine—hematologic cancer	3.42e-05	0.013	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—MYBL2—hematologic cancer	3.39e-05	0.00417	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—POT1—hematologic cancer	3.39e-05	0.00417	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—GRB2—hematologic cancer	3.38e-05	0.00416	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFA—hematologic cancer	3.37e-05	0.00415	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK2—hematologic cancer	3.37e-05	0.00414	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—hematologic cancer	3.35e-05	0.00413	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinorelbine—Vincristine—hematologic cancer	3.32e-05	0.0126	CbGdCrCtD
Dexrazoxane—TOP2A—Vinorelbine—Vinblastine—hematologic cancer	3.32e-05	0.0126	CbGdCrCtD
Dexrazoxane—TOP2A—Teniposide—Etoposide—hematologic cancer	3.31e-05	0.0126	CbGdCrCtD
Dexrazoxane—TOP2A—Podofilox—Etoposide—hematologic cancer	3.31e-05	0.0126	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STAT5A—hematologic cancer	3.25e-05	0.004	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABL1—hematologic cancer	3.25e-05	0.004	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—hematologic cancer	3.22e-05	0.00397	CbGpPWpGaD
Dexrazoxane—TOP2A—Cladribine—Nelarabine—hematologic cancer	3.21e-05	0.0122	CbGdCrCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—hematologic cancer	3.18e-05	0.00392	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ATR—hematologic cancer	3.15e-05	0.00388	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—hematologic cancer	3.15e-05	0.00388	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—STAG2—hematologic cancer	3.14e-05	0.00387	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—hematologic cancer	3.06e-05	0.00377	CbGpPWpGaD
Dexrazoxane—TOP2A—Floxuridine—Cladribine—hematologic cancer	3.05e-05	0.0116	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF1—hematologic cancer	3.02e-05	0.00372	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—hematologic cancer	2.98e-05	0.00367	CbGpPWpGaD
Dexrazoxane—TOP2A—Clofarabine—Nelarabine—hematologic cancer	2.97e-05	0.0113	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—NCOR1—hematologic cancer	2.93e-05	0.00361	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFRA—hematologic cancer	2.93e-05	0.0036	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—hematologic cancer	2.92e-05	0.00359	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—H3F3B—hematologic cancer	2.87e-05	0.00354	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—FOXM1—hematologic cancer	2.87e-05	0.00354	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinblastine—Vinorelbine—hematologic cancer	2.85e-05	0.0109	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—hematologic cancer	2.84e-05	0.0035	CbGpPWpGaD
Dexrazoxane—TOP2A—Vincristine—Vinblastine—hematologic cancer	2.83e-05	0.0108	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—hematologic cancer	2.83e-05	0.00348	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—STAG2—hematologic cancer	2.81e-05	0.00346	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PRKCG—hematologic cancer	2.8e-05	0.00345	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—hematologic cancer	2.77e-05	0.00341	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—hematologic cancer	2.74e-05	0.00337	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND3—hematologic cancer	2.72e-05	0.00334	CbGpPWpGaD
Dexrazoxane—TOP2A—Cytarabine—Clofarabine—hematologic cancer	2.69e-05	0.0102	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—FAS—hematologic cancer	2.63e-05	0.00324	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—NUP98—hematologic cancer	2.59e-05	0.00318	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—FOXM1—hematologic cancer	2.57e-05	0.00316	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—H3F3B—hematologic cancer	2.57e-05	0.00316	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—hematologic cancer	2.55e-05	0.00314	CbGpPWpGaD
Dexrazoxane—TOP2A—Cytarabine—Nelarabine—hematologic cancer	2.53e-05	0.00963	CbGdCrCtD
Dexrazoxane—TOP2A—Cladribine—Fludarabine—hematologic cancer	2.51e-05	0.00956	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—NUP214—hematologic cancer	2.49e-05	0.00307	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—NPM1—hematologic cancer	2.47e-05	0.00304	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK14—hematologic cancer	2.45e-05	0.00301	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN2A—hematologic cancer	2.43e-05	0.00299	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND3—hematologic cancer	2.43e-05	0.00299	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—hematologic cancer	2.42e-05	0.00298	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—hematologic cancer	2.41e-05	0.00297	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—hematologic cancer	2.4e-05	0.00296	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BAD—hematologic cancer	2.34e-05	0.00288	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—hematologic cancer	2.34e-05	0.00288	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—hematologic cancer	2.34e-05	0.00288	CbGpPWpGaD
Dexrazoxane—TOP2A—Clofarabine—Fludarabine—hematologic cancer	2.32e-05	0.00884	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—hematologic cancer	2.31e-05	0.00285	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—NUP98—hematologic cancer	2.31e-05	0.00285	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinblastine—Vincristine—hematologic cancer	2.28e-05	0.00869	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—NUP214—hematologic cancer	2.23e-05	0.00274	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—SMC1A—hematologic cancer	2.2e-05	0.00271	CbGpPWpGaD
Dexrazoxane—TOP2A—Clofarabine—Cytarabine—hematologic cancer	2.19e-05	0.00834	CbGdCrCtD
Dexrazoxane—TOP2A—Azacitidine—Pentostatin—hematologic cancer	2.16e-05	0.00824	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	2.16e-05	0.00266	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—H3F3A—hematologic cancer	2.16e-05	0.00265	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—hematologic cancer	2.15e-05	0.00265	CbGpPWpGaD
Dexrazoxane—TOP2A—Clofarabine—Cladribine—hematologic cancer	2.13e-05	0.00813	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	2.11e-05	0.0026	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	2.1e-05	0.00259	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CREB1—hematologic cancer	2.07e-05	0.00255	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—hematologic cancer	2.05e-05	0.00253	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MLH1—hematologic cancer	2.05e-05	0.00253	CbGpPWpGaD
Dexrazoxane—TOP2A—Gemcitabine—Cytarabine—hematologic cancer	2.03e-05	0.00773	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK6—hematologic cancer	2.02e-05	0.00249	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	2.01e-05	0.00247	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—hematologic cancer	1.99e-05	0.00245	CbGpPWpGaD
Dexrazoxane—TOP2A—Cytarabine—Fludarabine—hematologic cancer	1.97e-05	0.00752	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—SMC1A—hematologic cancer	1.97e-05	0.00242	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—H3F3A—hematologic cancer	1.93e-05	0.00237	CbGpPWpGaD
Dexrazoxane—TOP2A—Azacitidine—Clofarabine—hematologic cancer	1.93e-05	0.00734	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—hematologic cancer	1.92e-05	0.00237	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	1.91e-05	0.00235	CbGpPWpGaD
Dexrazoxane—TOP2A—Cytarabine—Gemcitabine—hematologic cancer	1.86e-05	0.0071	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HSP90AA1—hematologic cancer	1.81e-05	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.81e-05	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Azacitidine—Nelarabine—hematologic cancer	1.81e-05	0.0069	CbGdCrCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK6—hematologic cancer	1.81e-05	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.79e-05	0.0022	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND2—hematologic cancer	1.74e-05	0.00214	CbGpPWpGaD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—hematologic cancer	1.73e-05	0.00658	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—hematologic cancer	1.73e-05	0.00658	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—hematologic cancer	1.73e-05	0.00658	CbGdCrCtD
Dexrazoxane—Urticaria—Etoposide—hematologic cancer	1.68e-05	0.000137	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—hematologic cancer	1.67e-05	0.000137	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—hematologic cancer	1.67e-05	0.000137	CcSEcCtD
Dexrazoxane—Malaise—Prednisone—hematologic cancer	1.67e-05	0.000136	CcSEcCtD
Dexrazoxane—Body temperature increased—Etoposide—hematologic cancer	1.67e-05	0.000136	CcSEcCtD
Dexrazoxane—Abdominal pain—Etoposide—hematologic cancer	1.67e-05	0.000136	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—hematologic cancer	1.66e-05	0.000136	CcSEcCtD
Dexrazoxane—Syncope—Prednisone—hematologic cancer	1.66e-05	0.000136	CcSEcCtD
Dexrazoxane—Vomiting—Vincristine—hematologic cancer	1.66e-05	0.000135	CcSEcCtD
Dexrazoxane—Anorexia—Dexamethasone—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—Anorexia—Betamethasone—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—Urticaria—Prednisolone—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—Asthenia—Cisplatin—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—Cardiac disorder—Methotrexate—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—Fatigue—Triamcinolone—hematologic cancer	1.65e-05	0.000135	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—hematologic cancer	1.65e-05	0.00203	CbGpPWpGaD
Dexrazoxane—Oedema peripheral—Epirubicin—hematologic cancer	1.64e-05	0.000134	CcSEcCtD
Dexrazoxane—Pain—Triamcinolone—hematologic cancer	1.64e-05	0.000134	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—hematologic cancer	1.64e-05	0.000134	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	1.63e-05	0.00201	CbGpPWpGaD
Dexrazoxane—Headache—Vincristine—hematologic cancer	1.63e-05	0.000133	CcSEcCtD
Dexrazoxane—Loss of consciousness—Prednisone—hematologic cancer	1.63e-05	0.000133	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—HSP90AA1—hematologic cancer	1.62e-05	0.002	CbGpPWpGaD
Dexrazoxane—Nausea—Carmustine—hematologic cancer	1.62e-05	0.000132	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—hematologic cancer	1.61e-05	0.000132	CcSEcCtD
Dexrazoxane—Vomiting—Irinotecan—hematologic cancer	1.61e-05	0.000132	CcSEcCtD
Dexrazoxane—Vomiting—Mitoxantrone—hematologic cancer	1.61e-05	0.000132	CcSEcCtD
Dexrazoxane—Nausea—Alitretinoin—hematologic cancer	1.61e-05	0.000131	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—hematologic cancer	1.6e-05	0.000131	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—hematologic cancer	1.6e-05	0.000131	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	1.6e-05	0.00197	CbGpPWpGaD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—hematologic cancer	1.6e-05	0.00609	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—hematologic cancer	1.6e-05	0.00609	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—hematologic cancer	1.6e-05	0.00609	CbGdCrCtD
Dexrazoxane—Headache—Irinotecan—hematologic cancer	1.59e-05	0.00013	CcSEcCtD
Dexrazoxane—Headache—Mitoxantrone—hematologic cancer	1.59e-05	0.00013	CcSEcCtD
Dexrazoxane—Nausea—Ifosfamide—hematologic cancer	1.59e-05	0.00013	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.58e-05	0.000129	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.58e-05	0.000129	CcSEcCtD
Dexrazoxane—Myalgia—Prednisone—hematologic cancer	1.58e-05	0.000129	CcSEcCtD
Dexrazoxane—Feeling abnormal—Triamcinolone—hematologic cancer	1.58e-05	0.000129	CcSEcCtD
Dexrazoxane—Diarrhoea—Cisplatin—hematologic cancer	1.58e-05	0.000129	CcSEcCtD
Dexrazoxane—Alopecia—Methotrexate—hematologic cancer	1.57e-05	0.000128	CcSEcCtD
Dexrazoxane—Vomiting—Gemcitabine—hematologic cancer	1.57e-05	0.000128	CcSEcCtD
Dexrazoxane—Insomnia—Dexamethasone—hematologic cancer	1.57e-05	0.000128	CcSEcCtD
Dexrazoxane—Insomnia—Betamethasone—hematologic cancer	1.57e-05	0.000128	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.57e-05	0.000128	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2B—hematologic cancer	1.56e-05	0.00192	CbGpPWpGaD
Dexrazoxane—Discomfort—Prednisone—hematologic cancer	1.56e-05	0.000127	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—hematologic cancer	1.56e-05	0.000127	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	1.56e-05	0.00192	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND2—hematologic cancer	1.56e-05	0.00192	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	1.55e-05	0.00191	CbGpPWpGaD
Dexrazoxane—Malnutrition—Methotrexate—hematologic cancer	1.55e-05	0.000126	CcSEcCtD
Dexrazoxane—Erythema—Methotrexate—hematologic cancer	1.55e-05	0.000126	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—hematologic cancer	1.55e-05	0.000126	CcSEcCtD
Dexrazoxane—Headache—Gemcitabine—hematologic cancer	1.55e-05	0.000126	CcSEcCtD
Dexrazoxane—Nausea—Vincristine—hematologic cancer	1.55e-05	0.000126	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—hematologic cancer	1.54e-05	0.000126	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—hematologic cancer	1.54e-05	0.000126	CcSEcCtD
Dexrazoxane—Urticaria—Triamcinolone—hematologic cancer	1.52e-05	0.000124	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—hematologic cancer	1.52e-05	0.000124	CcSEcCtD
Dexrazoxane—Asthenia—Etoposide—hematologic cancer	1.51e-05	0.000124	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—hematologic cancer	1.51e-05	0.000124	CcSEcCtD
Dexrazoxane—Body temperature increased—Triamcinolone—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—Decreased appetite—Dexamethasone—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—Decreased appetite—Betamethasone—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—Nausea—Mitoxantrone—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—Nausea—Irinotecan—hematologic cancer	1.51e-05	0.000123	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	1.51e-05	0.00185	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	1.5e-05	0.00185	CbGpPWpGaD
Dexrazoxane—Infection—Prednisone—hematologic cancer	1.5e-05	0.000123	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Epirubicin—hematologic cancer	1.5e-05	0.000122	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.5e-05	0.000122	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.5e-05	0.000122	CcSEcCtD
Dexrazoxane—Fatigue—Dexamethasone—hematologic cancer	1.5e-05	0.000122	CcSEcCtD
Dexrazoxane—Fatigue—Betamethasone—hematologic cancer	1.5e-05	0.000122	CcSEcCtD
Dexrazoxane—Pruritus—Etoposide—hematologic cancer	1.49e-05	0.000122	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—JUN—hematologic cancer	1.49e-05	0.00184	CbGpPWpGaD
Dexrazoxane—Shock—Prednisone—hematologic cancer	1.49e-05	0.000121	CcSEcCtD
Dexrazoxane—Pain—Betamethasone—hematologic cancer	1.48e-05	0.000121	CcSEcCtD
Dexrazoxane—Pain—Dexamethasone—hematologic cancer	1.48e-05	0.000121	CcSEcCtD
Dexrazoxane—Nervous system disorder—Prednisone—hematologic cancer	1.48e-05	0.000121	CcSEcCtD
Dexrazoxane—Alopecia—Epirubicin—hematologic cancer	1.47e-05	0.00012	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	1.47e-05	0.00181	CbGpPWpGaD
Dexrazoxane—Skin disorder—Prednisone—hematologic cancer	1.47e-05	0.00012	CcSEcCtD
Dexrazoxane—Nausea—Gemcitabine—hematologic cancer	1.47e-05	0.00012	CcSEcCtD
Dexrazoxane—Vomiting—Cisplatin—hematologic cancer	1.46e-05	0.00012	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—hematologic cancer	1.46e-05	0.000119	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—hematologic cancer	1.45e-05	0.000118	CcSEcCtD
Dexrazoxane—Malnutrition—Epirubicin—hematologic cancer	1.45e-05	0.000118	CcSEcCtD
Dexrazoxane—Diarrhoea—Etoposide—hematologic cancer	1.44e-05	0.000118	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—hematologic cancer	1.44e-05	0.00178	CbGpPWpGaD
Dexrazoxane—Anorexia—Prednisone—hematologic cancer	1.44e-05	0.000118	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Methotrexate—hematologic cancer	1.44e-05	0.000117	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	1.43e-05	0.00176	CbGpPWpGaD
Dexrazoxane—Anaemia—Methotrexate—hematologic cancer	1.43e-05	0.000117	CcSEcCtD
Dexrazoxane—Feeling abnormal—Dexamethasone—hematologic cancer	1.43e-05	0.000117	CcSEcCtD
Dexrazoxane—Feeling abnormal—Betamethasone—hematologic cancer	1.43e-05	0.000117	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—hematologic cancer	1.43e-05	0.000117	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.42e-05	0.000116	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Betamethasone—hematologic cancer	1.42e-05	0.000116	CcSEcCtD
Dexrazoxane—TOP2A—Azacitidine—Fludarabine—hematologic cancer	1.41e-05	0.00539	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—MAPK8—hematologic cancer	1.41e-05	0.00174	CbGpPWpGaD
Dexrazoxane—Angiopathy—Doxorubicin—hematologic cancer	1.4e-05	0.000114	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—hematologic cancer	1.4e-05	0.000114	CcSEcCtD
Dexrazoxane—Dizziness—Etoposide—hematologic cancer	1.39e-05	0.000114	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2B—hematologic cancer	1.39e-05	0.00172	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	1.39e-05	0.00172	CbGpPWpGaD
Dexrazoxane—Mediastinal disorder—Doxorubicin—hematologic cancer	1.39e-05	0.000113	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—hematologic cancer	1.39e-05	0.000113	CcSEcCtD
Dexrazoxane—Urticaria—Dexamethasone—hematologic cancer	1.38e-05	0.000113	CcSEcCtD
Dexrazoxane—Urticaria—Betamethasone—hematologic cancer	1.38e-05	0.000113	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.38e-05	0.000112	CcSEcCtD
Dexrazoxane—Dizziness—Prednisolone—hematologic cancer	1.38e-05	0.000112	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—EP300—hematologic cancer	1.38e-05	0.00169	CbGpPWpGaD
Dexrazoxane—Asthenia—Triamcinolone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Body temperature increased—Dexamethasone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Abdominal pain—Dexamethasone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Body temperature increased—Betamethasone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Abdominal pain—Betamethasone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Nausea—Cisplatin—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Insomnia—Prednisone—hematologic cancer	1.37e-05	0.000112	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—hematologic cancer	1.36e-05	0.000111	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	1.36e-05	0.00167	CbGpPWpGaD
Dexrazoxane—Pruritus—Triamcinolone—hematologic cancer	1.35e-05	0.000111	CcSEcCtD
Dexrazoxane—Cough—Methotrexate—hematologic cancer	1.35e-05	0.00011	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—hematologic cancer	1.35e-05	0.00011	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—BIRC5—hematologic cancer	1.35e-05	0.00166	CbGpPWpGaD
Dexrazoxane—Ill-defined disorder—Epirubicin—hematologic cancer	1.34e-05	0.00011	CcSEcCtD
Dexrazoxane—Vomiting—Etoposide—hematologic cancer	1.34e-05	0.000109	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—hematologic cancer	1.34e-05	0.000109	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—hematologic cancer	1.34e-05	0.000109	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—hematologic cancer	1.34e-05	0.000109	CcSEcCtD
Dexrazoxane—TOP2A—Azacitidine—Gemcitabine—hematologic cancer	1.34e-05	0.00509	CbGdCrCtD
Dexrazoxane—TOP2A—Azacitidine—Cytarabine—hematologic cancer	1.34e-05	0.00509	CbGdCrCtD
Dexrazoxane—Headache—Etoposide—hematologic cancer	1.32e-05	0.000108	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—hematologic cancer	1.32e-05	0.000108	CcSEcCtD
Dexrazoxane—Decreased appetite—Prednisone—hematologic cancer	1.31e-05	0.000107	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.31e-05	0.000107	CcSEcCtD
Dexrazoxane—Malaise—Epirubicin—hematologic cancer	1.31e-05	0.000107	CcSEcCtD
Dexrazoxane—Fatigue—Prednisone—hematologic cancer	1.3e-05	0.000106	CcSEcCtD
Dexrazoxane—Headache—Prednisolone—hematologic cancer	1.3e-05	0.000106	CcSEcCtD
Dexrazoxane—Discomfort—Methotrexate—hematologic cancer	1.3e-05	0.000106	CcSEcCtD
Dexrazoxane—TOP2A—Azacitidine—Cladribine—hematologic cancer	1.3e-05	0.00496	CbGdCrCtD
Dexrazoxane—Syncope—Epirubicin—hematologic cancer	1.3e-05	0.000106	CcSEcCtD
Dexrazoxane—Leukopenia—Epirubicin—hematologic cancer	1.3e-05	0.000106	CcSEcCtD
Dexrazoxane—Constipation—Prednisone—hematologic cancer	1.29e-05	0.000106	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.28e-05	0.00158	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Epirubicin—hematologic cancer	1.27e-05	0.000104	CcSEcCtD
Dexrazoxane—Dizziness—Triamcinolone—hematologic cancer	1.27e-05	0.000103	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—hematologic cancer	1.26e-05	0.000103	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—hematologic cancer	1.26e-05	0.000102	CcSEcCtD
Dexrazoxane—Nausea—Etoposide—hematologic cancer	1.25e-05	0.000102	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.25e-05	0.00154	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Prednisone—hematologic cancer	1.25e-05	0.000102	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.25e-05	0.00153	CbGpPWpGaD
Dexrazoxane—Asthenia—Betamethasone—hematologic cancer	1.25e-05	0.000102	CcSEcCtD
Dexrazoxane—Asthenia—Dexamethasone—hematologic cancer	1.25e-05	0.000102	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—hematologic cancer	1.24e-05	0.000102	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—hematologic cancer	1.24e-05	0.000101	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—hematologic cancer	1.24e-05	0.000101	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—hematologic cancer	1.24e-05	0.000101	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Prednisone—hematologic cancer	1.24e-05	0.000101	CcSEcCtD
Dexrazoxane—Nausea—Prednisolone—hematologic cancer	1.24e-05	0.000101	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK2—hematologic cancer	1.23e-05	0.00152	CbGpPWpGaD
Dexrazoxane—Myalgia—Epirubicin—hematologic cancer	1.23e-05	0.000101	CcSEcCtD
Dexrazoxane—Pruritus—Dexamethasone—hematologic cancer	1.23e-05	0.0001	CcSEcCtD
Dexrazoxane—Pruritus—Betamethasone—hematologic cancer	1.23e-05	0.0001	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—hematologic cancer	1.23e-05	0.0001	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.22e-05	0.0001	CcSEcCtD
Dexrazoxane—Discomfort—Epirubicin—hematologic cancer	1.22e-05	9.95e-05	CcSEcCtD
Dexrazoxane—Vomiting—Triamcinolone—hematologic cancer	1.22e-05	9.93e-05	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—hematologic cancer	1.21e-05	9.87e-05	CcSEcCtD
Dexrazoxane—Dry mouth—Epirubicin—hematologic cancer	1.21e-05	9.85e-05	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—hematologic cancer	1.2e-05	9.83e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—BIRC5—hematologic cancer	1.2e-05	0.00148	CbGpPWpGaD
Dexrazoxane—Syncope—Doxorubicin—hematologic cancer	1.2e-05	9.81e-05	CcSEcCtD
Dexrazoxane—Urticaria—Prednisone—hematologic cancer	1.2e-05	9.81e-05	CcSEcCtD
Dexrazoxane—Leukopenia—Doxorubicin—hematologic cancer	1.2e-05	9.8e-05	CcSEcCtD
Dexrazoxane—Headache—Triamcinolone—hematologic cancer	1.2e-05	9.79e-05	CcSEcCtD
Dexrazoxane—Abdominal pain—Prednisone—hematologic cancer	1.2e-05	9.76e-05	CcSEcCtD
Dexrazoxane—Body temperature increased—Prednisone—hematologic cancer	1.2e-05	9.76e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Betamethasone—hematologic cancer	1.19e-05	9.7e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Dexamethasone—hematologic cancer	1.19e-05	9.7e-05	CcSEcCtD
Dexrazoxane—Loss of consciousness—Doxorubicin—hematologic cancer	1.18e-05	9.62e-05	CcSEcCtD
Dexrazoxane—Infection—Epirubicin—hematologic cancer	1.17e-05	9.59e-05	CcSEcCtD
Dexrazoxane—Cough—Doxorubicin—hematologic cancer	1.17e-05	9.55e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—hematologic cancer	1.17e-05	0.00144	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—hematologic cancer	1.17e-05	0.00144	CbGpPWpGaD
Dexrazoxane—Shock—Epirubicin—hematologic cancer	1.16e-05	9.5e-05	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.16e-05	0.00143	CbGpPWpGaD
Dexrazoxane—Nervous system disorder—Epirubicin—hematologic cancer	1.16e-05	9.47e-05	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—hematologic cancer	1.16e-05	9.45e-05	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.15e-05	0.00142	CbGpPWpGaD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.15e-05	9.4e-05	CcSEcCtD
Dexrazoxane—Skin disorder—Epirubicin—hematologic cancer	1.15e-05	9.38e-05	CcSEcCtD
Dexrazoxane—Dizziness—Dexamethasone—hematologic cancer	1.15e-05	9.37e-05	CcSEcCtD
Dexrazoxane—Dizziness—Betamethasone—hematologic cancer	1.15e-05	9.37e-05	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—hematologic cancer	1.14e-05	9.33e-05	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—hematologic cancer	1.14e-05	9.32e-05	CcSEcCtD
Dexrazoxane—Nausea—Triamcinolone—hematologic cancer	1.14e-05	9.28e-05	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.13e-05	9.25e-05	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—hematologic cancer	1.13e-05	9.21e-05	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—hematologic cancer	1.13e-05	9.2e-05	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—hematologic cancer	1.13e-05	9.2e-05	CcSEcCtD
Dexrazoxane—Somnolence—Methotrexate—hematologic cancer	1.12e-05	9.17e-05	CcSEcCtD
Dexrazoxane—Dry mouth—Doxorubicin—hematologic cancer	1.12e-05	9.11e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK2—hematologic cancer	1.1e-05	0.00136	CbGpPWpGaD
Dexrazoxane—Vomiting—Betamethasone—hematologic cancer	1.1e-05	9.01e-05	CcSEcCtD
Dexrazoxane—Vomiting—Dexamethasone—hematologic cancer	1.1e-05	9.01e-05	CcSEcCtD
Dexrazoxane—Decreased appetite—Methotrexate—hematologic cancer	1.1e-05	8.97e-05	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.09e-05	8.91e-05	CcSEcCtD
Dexrazoxane—Fatigue—Methotrexate—hematologic cancer	1.09e-05	8.89e-05	CcSEcCtD
Dexrazoxane—Headache—Betamethasone—hematologic cancer	1.09e-05	8.88e-05	CcSEcCtD
Dexrazoxane—Headache—Dexamethasone—hematologic cancer	1.09e-05	8.88e-05	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—hematologic cancer	1.09e-05	8.87e-05	CcSEcCtD
Dexrazoxane—Asthenia—Prednisone—hematologic cancer	1.08e-05	8.86e-05	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—hematologic cancer	1.08e-05	8.82e-05	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.08e-05	8.79e-05	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—hematologic cancer	1.08e-05	8.79e-05	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—hematologic cancer	1.07e-05	8.76e-05	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—hematologic cancer	1.07e-05	8.75e-05	CcSEcCtD
Dexrazoxane—Pruritus—Prednisone—hematologic cancer	1.07e-05	8.73e-05	CcSEcCtD
Dexrazoxane—Insomnia—Epirubicin—hematologic cancer	1.07e-05	8.73e-05	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—hematologic cancer	1.06e-05	8.68e-05	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.06e-05	0.0013	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Epirubicin—hematologic cancer	1.05e-05	8.61e-05	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—hematologic cancer	1.05e-05	8.58e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—ATM—hematologic cancer	1.05e-05	0.00129	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—hematologic cancer	1.04e-05	0.00128	CbGpPWpGaD
Dexrazoxane—Anorexia—Doxorubicin—hematologic cancer	1.04e-05	8.51e-05	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—hematologic cancer	1.04e-05	8.5e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Prednisone—hematologic cancer	1.03e-05	8.44e-05	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—hematologic cancer	1.03e-05	8.43e-05	CcSEcCtD
Dexrazoxane—Nausea—Betamethasone—hematologic cancer	1.03e-05	8.42e-05	CcSEcCtD
Dexrazoxane—Nausea—Dexamethasone—hematologic cancer	1.03e-05	8.42e-05	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—hematologic cancer	1.03e-05	8.39e-05	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.03e-05	0.00126	CbGpPWpGaD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.02e-05	8.33e-05	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—hematologic cancer	1.02e-05	8.32e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—hematologic cancer	1.01e-05	0.00125	CbGpPWpGaD
Dexrazoxane—Constipation—Epirubicin—hematologic cancer	1.01e-05	8.25e-05	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—hematologic cancer	1.01e-05	8.25e-05	CcSEcCtD
Dexrazoxane—Urticaria—Methotrexate—hematologic cancer	1e-05	8.19e-05	CcSEcCtD
Dexrazoxane—Dizziness—Prednisone—hematologic cancer	1e-05	8.16e-05	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—hematologic cancer	9.99e-06	8.15e-05	CcSEcCtD
Dexrazoxane—Abdominal pain—Methotrexate—hematologic cancer	9.99e-06	8.15e-05	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.97e-06	8.14e-05	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—hematologic cancer	9.9e-06	8.08e-05	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—hematologic cancer	9.84e-06	0.00121	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Doxorubicin—hematologic cancer	9.75e-06	7.96e-05	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—hematologic cancer	9.74e-06	7.95e-05	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—hematologic cancer	9.73e-06	7.94e-05	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—hematologic cancer	9.67e-06	7.89e-05	CcSEcCtD
Dexrazoxane—Vomiting—Prednisone—hematologic cancer	9.61e-06	7.85e-05	CcSEcCtD
Dexrazoxane—Decreased appetite—Doxorubicin—hematologic cancer	9.51e-06	7.76e-05	CcSEcCtD
Dexrazoxane—Headache—Prednisone—hematologic cancer	9.47e-06	7.73e-05	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.45e-06	7.71e-05	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—hematologic cancer	9.43e-06	7.7e-05	CcSEcCtD
Dexrazoxane—Urticaria—Epirubicin—hematologic cancer	9.39e-06	7.67e-05	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—hematologic cancer	9.36e-06	7.64e-05	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—hematologic cancer	9.36e-06	7.64e-05	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—hematologic cancer	9.35e-06	7.63e-05	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—hematologic cancer	9.35e-06	7.63e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RB1—hematologic cancer	9.07e-06	0.00112	CbGpPWpGaD
Dexrazoxane—Asthenia—Methotrexate—hematologic cancer	9.07e-06	7.4e-05	CcSEcCtD
Dexrazoxane—Feeling abnormal—Doxorubicin—hematologic cancer	9.02e-06	7.36e-05	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—hematologic cancer	9.01e-06	0.00111	CbGpPWpGaD
Dexrazoxane—Nausea—Prednisone—hematologic cancer	8.98e-06	7.33e-05	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.95e-06	7.3e-05	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—hematologic cancer	8.94e-06	7.3e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN2A—hematologic cancer	8.92e-06	0.0011	CbGpPWpGaD
Dexrazoxane—Urticaria—Doxorubicin—hematologic cancer	8.69e-06	7.1e-05	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	8.66e-06	0.00107	CbGpPWpGaD
Dexrazoxane—Abdominal pain—Doxorubicin—hematologic cancer	8.65e-06	7.06e-05	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—hematologic cancer	8.65e-06	7.06e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Methotrexate—hematologic cancer	8.64e-06	7.06e-05	CcSEcCtD
Dexrazoxane—Asthenia—Epirubicin—hematologic cancer	8.48e-06	6.93e-05	CcSEcCtD
Dexrazoxane—Pruritus—Epirubicin—hematologic cancer	8.37e-06	6.83e-05	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—hematologic cancer	8.36e-06	6.82e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Epirubicin—hematologic cancer	8.09e-06	6.6e-05	CcSEcCtD
Dexrazoxane—Vomiting—Methotrexate—hematologic cancer	8.03e-06	6.56e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDKN2A—hematologic cancer	7.98e-06	0.000982	CbGpPWpGaD
Dexrazoxane—TOP2A—Methyltestosterone—Prednisone—hematologic cancer	7.97e-06	0.00304	CbGdCrCtD
Dexrazoxane—Headache—Methotrexate—hematologic cancer	7.92e-06	6.46e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—hematologic cancer	7.9e-06	0.000972	CbGpPWpGaD
Dexrazoxane—Asthenia—Doxorubicin—hematologic cancer	7.85e-06	6.41e-05	CcSEcCtD
Dexrazoxane—Dizziness—Epirubicin—hematologic cancer	7.82e-06	6.38e-05	CcSEcCtD
Dexrazoxane—TOP2A—Methyltestosterone—Prednisolone—hematologic cancer	7.78e-06	0.00297	CbGdCrCtD
Dexrazoxane—Pruritus—Doxorubicin—hematologic cancer	7.74e-06	6.32e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—hematologic cancer	7.74e-06	0.000952	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—hematologic cancer	7.54e-06	0.000928	CbGpPWpGaD
Dexrazoxane—Vomiting—Epirubicin—hematologic cancer	7.52e-06	6.14e-05	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—hematologic cancer	7.5e-06	6.13e-05	CcSEcCtD
Dexrazoxane—Diarrhoea—Doxorubicin—hematologic cancer	7.49e-06	6.11e-05	CcSEcCtD
Dexrazoxane—Headache—Epirubicin—hematologic cancer	7.41e-06	6.05e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—hematologic cancer	7.29e-06	0.000897	CbGpPWpGaD
Dexrazoxane—Dizziness—Doxorubicin—hematologic cancer	7.23e-06	5.91e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—hematologic cancer	7.06e-06	0.00087	CbGpPWpGaD
Dexrazoxane—Nausea—Epirubicin—hematologic cancer	7.02e-06	5.73e-05	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—hematologic cancer	6.96e-06	5.68e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—EP300—hematologic cancer	6.94e-06	0.000854	CbGpPWpGaD
Dexrazoxane—Headache—Doxorubicin—hematologic cancer	6.85e-06	5.6e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—hematologic cancer	6.74e-06	0.00083	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—hematologic cancer	6.52e-06	0.000802	CbGpPWpGaD
Dexrazoxane—Nausea—Doxorubicin—hematologic cancer	6.5e-06	5.31e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK3—hematologic cancer	6.22e-06	0.000765	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—EP300—hematologic cancer	6.2e-06	0.000764	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—hematologic cancer	6.05e-06	0.000744	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK3—hematologic cancer	5.56e-06	0.000684	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—hematologic cancer	5.41e-06	0.000665	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—hematologic cancer	4.44e-06	0.000546	CbGpPWpGaD
